Patent · US Active

Pain treatment

US9518260B2 · kind B2 · utility

2Cited by

0References

25Claims

0Family size

Assignee

Benitec Biopharma Limited · AU

Inventors

Peter French · Sydney, AU
Michael Wayne Graham · Jindalee, AU

Key dates

Filing date	Feb 28, 2013
Grant date	Dec 13, 2016
Priority date	—
Expiry date	Feb 28, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/531
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The disclosure relates to an RNA interference (RNAi) agent and the use of that RNAi agent to treat chronic pain in individuals, as well as pharmaceutical compositions containing the RNAi agents of the invention. The DNA-directed RNA interference (ddRNAi) agent for inhibiting expression of one or more target sequences in a pain associated gene comprises, one or more effector sequence sequences and effector complement sequences of at least 17 nucleotides in length, wherein the effector sequence is substantially complementary to the predicted transcript of a target sequence within a pain associated gene.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.